(Last Updated On: March 18, 2021)

Angela Katrina M. Esguerra, MD, FPDS and Elaine Melody T. Co, MD, MBA

ABSTRACT

Introduction: Erythema multiforme has been known as an infection or drug-associated mucocutaneous eruption characterized by target lesions. A clinical entity, known as Mycoplasma-induced rash and mucositis seen mostly in the pediatric population is emerging and may be associated with atypical pneumonia caused by Mycoplasma pneumoniae. This presents with features overlapping with erythema multiforme and SJS-TEN spectrum but with a different trigger, prognosis, and recurrence rate.

Case summary: Target lesions in the clinical setting are usually characteristically associated with erythema multiforme, a mucocutaneous condition associated with an underlying infectious trigger. We present a case of a 10-year-old Filipino boy who was initially diagnosed with erythema multiforme
major. Eventual testing for the etiology of the underlying infection, Mycoplasma pneumoniae, proved to be a useful diagnostic that gave a better grasp on the case’s mechanism, sequela, and prognosis. The patient was admitted for pneumonia and his presenting mucositis was severe. Cutaneously, he had atypical target and few target lesions on the trunk and extremities. He was diagnosed as a case of
Mycoplasma-induced rash and mucositis (MIRM) and treated with antibiotics and systemic steroids for which he recovered fully in three weeks. MIRM should be separated from erythema multiforme, Stevens Johnsons syndrome and toxic epidermal necrolysis as it follows a different disease course.

Conclusion: Mycoplasma-induced rash and mucositis is now considered a distinct entity despite it having overlapping features with erythema multiforme and SJS-TEN spectrum. It presents usually in the younger age group with absent to sparse atypical vesiculobullous or targetoid lesions, significant mucosal involvement, and confluent necrosis on histology. It is important to identify it as a trigger because of its more frequent and severe mucosal sequelae. Management includes symptomatic relief, antibiotic therapy with a macrolide in the presence of pneumonia and systemic steroids when mucositis is severe. Majority of patients achieve full recovery.

Keywords: Mycoplasma-induced rash and mucositis, MIRM, RIME, Mycoplasma pneumoniae, erythema multiforme spectrum, atypical targets, target lesions

Citation:
Esguerra, AKM, Co, EMT. A case report of a successfully treated Myoplasma-induced rash and mucositis (MIRM) in a 10-year old Filipino. J Phil Dermatol Soc 2019, 29(2), 59-62

1. Bhoopalan S, Chawla V, Hogan M, Wilson N, Das S. Bullous Skin Manifestations of Mycoplasma pneumoniae Infection: A Case Series. Journal of Investigative Medicine High Impact Case Reports. 2017;5(3):232470961772775
2. Martínez-Pérez M, Imbernón-Moya A, Lobato-Berezo A, Churruca- Grijelmo M. Mycoplasma pneumoniae -Induced Mucocutaneous Rash: A New Syndrome Distinct from Erythema Multiforme? Report of a New Case and Review of the Literature. Actas Dermosifiliogr (English Edition). 2016;107(7):e47-e51.
3. Bastuji-Garin S. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-96.
4. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau J. Correlations Between Clinical Patterns and Causes of Erythema Multiforme Majus, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis. Arch Dermatol. 2002;138(8).
5. Canavan T, Mathes E, Frieden I, Shinkai K. Mycoplasma pneumoniae– induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: A systematic review. J Am Acad Dermatol. 2015;72(2):239-245.e4.
6. Ramien M, Bruckner A. Mucocutaneous Eruptions in Acutely Ill Pediatric Patients—Think of Mycoplasma pneumoniae (and Other Infections) First. JAMA Dermatol. 2020;156(2):124.
7. Amode R, Ingen-Housz-Oro S, Ortonne N, Bounfour T, Pereyre S, Schlemmer F, Bequignon E, Royer G, Wolkenstein P, Chosidow O. Clinical and histologic features of Mycoplasma pneumoniae –related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes. J Am Acad Dermatol. 2018;79(1):110 117.
8. Schalock P, Dinulos J, Pace N, Schwarzenberger K, Wenger J. Erythema Multiforme due to Mycoplasma pneumoniae Infection in Two Children. Pediatr Dermatol. 2006;23(6):546-555.
9. Sokumbi O, Wetter D. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol. 2012;51(8):889-902.
10. Meyer Sauteur P, Theiler M, Buettcher M, Seiler M, Weibel L, Berger C. Frequency and Clinical Presentation of Mucocutaneous Disease Due to Mycoplasma pneumoniae Infection in Children With Community- Acquired Pneumonia. JAMA Dermatol. 2020;156(2):144.
11. Kang S, Amagai M, Bruckner A, Enk A, Margolis D, McMichael A, Orringer J. Fitzpatrick’s dermatology in general medicine, 9e. Chapter 43. New York, N.Y.: McGraw-Hill Education LLC; 2019.
12. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clin Rev Allerg Immu. 2017;54(1):147-176.

More Articles

A randomized, double-blind, comparative study on the safety and efficacy of virgin coconut (Cocos nucifera l.) oil against 1% hydrocortisone lotion as an anti-inflammatory and antipruritic preparation for mosquito reactions

  Authors: Uy, Veronica S, MD; Gracia B. Teodosio, MD, FPDS; Ma. Teresita G. Gabriel, MD, FPDS; Mary Catherine T. Galang, MD; Mohammad Yoga A. Waskito, MD; Johannes F. Dayrit, MD, FPDS     Abstract Background: Virgin coconut oil (VCO) has been reported...

read more